The gene-editing technology known as CRISPR has attracted much excitement and investor interest with its potential to someday treat diseases by fixing faulty copies of genes. But recently, a different approach called RNA editing, which could offer advantages over CRISPR, has been gaining ground in academic labs and start-ups, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.
RNA editing uses an enzyme called ADAR to make precise edits to RNA, the shorter-lived cousin to DNA that acts as a blueprint for proteins. Researchers direct ADAR to specific RNAs with a guide sequence attached to the enzyme. Unlike CRISPR gene editing, the effects of RNA editing are reversible because cells are constantly making new copies of RNA. Therefore, RNA editing avoids the risks of permanent gene editing with CRISPR, writes Assistant Editor Ryan Cross, and could also be used to treat temporary conditions, such as pain or inflammation.
However, finding an easy way to control how ADAR makes its edits has been challenging. Researchers have tried chemically attaching ADAR to a guide RNA, adding an RNA-binding protein or even linking the catalytic portion of ADAR to the bacterial Cas9 enzyme used in CRISPR. However, these approaches require getting the modified enzymes into human cells. Some researchers are working on using human cells’ own ADAR for RNA editing, by introducing chemically modified guide RNAs that recruit the editing enzyme and direct it to specific RNAs. With researchers and investors becoming increasingly interested in this approach, RNA editing could someday give CRISPR a run for its money, Cross writes.
The article, “Watch out, CRISPR. The RNA editing race is on,” is freely available here.
Learn more: Interest in RNA editing heats up
The Latest on: RNA editing
via Google News
The Latest on: RNA editing
- Gene editing shows potential to correct mutations causing inherited retinal degenerationon January 20, 2021 at 5:11 am
Cas systems, offer the potential to correct mutations causing inherited retinal degenerations, a leading cause of blindness.
- Gene Editing Hold Potential to Correct Retinal Degenerationson January 19, 2021 at 10:14 pm
Genome editing therapies offer the potential to correct mutations causing inherited retinal degenerations, which could lead to blindness.
- Genome editing to treat human retinal degenerationon January 19, 2021 at 1:57 pm
Cas systems, offer the potential to correct mutations causing inherited retinal degenerations, a leading cause of blindness. Technological advances in gene editing, continuing safety concerns, and str ...
- Scientists find new mechanism of cancer formationon January 19, 2021 at 9:35 am
A team of scientists at the National University of Singapore (NUS), led by Dr. Polly Leilei Chen from the Cancer Science Institute of Singapore and Yong Loo Lin School of Medicine at NUS, has ...
- Shape Therapeutics to Emphasize RNA Editing Technology Platform advancement in Parkinson’s disease and the identification of novelon January 11, 2021 at 5:41 pm
Shape Therapeutics to Emphasize RNA Editing Technology Platform advancement in Parkinson's disease and the identification of novel ...
- Shape Therapeutics to Highlight RNA Editing Technology Platform Advancements in Parkinson’s Disease and the Identification of Novel CNS-targeting AAV Variants at the J.P ...on January 11, 2021 at 9:00 am
Shape Therapeutics Inc. (ShapeTX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P.
- Smith Researches RNA Editing in Trypanosoma Bruceion January 6, 2021 at 12:32 pm
Joseph Terrell Smith Jr., PhD, postdoctoral fellow in microbiology and immunology, has been awarded a three-year, $202,000 F32 grant from the National Institute of Allergy and Infectious Diseases to ...
- RNA Editing Market 2020 Overview, Growth Factors, Demand and Trends Forecast Report till 2024 | Radiant Insights, Inc.on December 16, 2020 at 3:05 pm
According to new report available with Radiant Insights, the RNA Editing market report provides in-depth analysis of market by production, share, size, demand, economic trends, feasibility ...
- Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officeron December 8, 2020 at 5:04 am
The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix™, a precision RNA editing technology using ...
- Industry-Led Conference for all those in RNA Editingon November 30, 2020 at 4:01 pm
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible.
via Bing News